Argenx pullback brings ‘attractive buying opportunity,’ says Citi

Citi analyst Samantha Semenkow believes the growth story for Argenx (ARGX) remains intact and that concerns surrounding a slowing Vyvgart launch are overblown. The firm sees a “meaningful buying opportunity” on expectations of continued Vyvgart growth and a favorable risk/reward for the shares into pipeline readouts. The recent prefilled syringe approval with a “best-case label” and continued expansion of the chronic inflammatory demyelinating polyneuropathy launch should drive Vyvgart momentum over the near-term, the analyst tells investors in a research note. Citi reiterates a Buy rating on Argenx with a $803 and believes the recent pullback offers an “attractive buying opportunity.”